Related Experiment Videos

Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization

H M Ross1, L W Weber, S Wang

  • 1The Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

Insights

DNA immunization using a gene gun effectively generates cytotoxic T lymphocyte (CTL) responses. This method successfully rejected established tumors in mice, highlighting its potential for cancer immunotherapy.

Area of Science:

  • Immunology
  • Cancer Research
  • Gene Therapy

Background:

  • DNA immunization elicits antibody and cytotoxic T lymphocyte (CTL) responses against infectious agents.
  • CTL responses play a role in cancer rejection.
  • Particle bombardment (gene gun) is a method for DNA delivery.

Purpose of the Study:

  • To investigate if DNA immunization via particle bombardment can induce CTL responses capable of rejecting tumors in mice.
  • To assess the potency of DNA immunization for CTL induction compared to peptide immunization.
  • To determine if DNA immunization can reject established tumors.

Main Methods:

  • Mice were immunized using DNA encoding beta-galactosidase or ovalbumin via particle bombardment.
  • CTL responses were generated in DBA/2 and C57BL/6 mouse strains.
  • Mice were challenged with tumors expressing beta-galactosidase.
  • Tumor rejection was assessed, and the role of CD8(+) T cells was confirmed.

Main Results:

  • DNA immunization via particle bombardment primed mice to generate CTLs.
  • This method was more potent in inducing CTLs than optimized peptide immunization.
  • DNA immunization protected mice against established tumors expressing beta-galactosidase.
  • Tumor rejection occurred even when immunization started after tumor establishment.
  • Tumor rejection was dependent on CD8(+) T cells.

Conclusions:

  • DNA immunization by particle bombardment efficiently induces potent CTL responses.
  • This approach can lead to the rejection of established tumors in a mouse model.
  • DNA immunization represents a promising strategy for cancer immunotherapy.

Related Concept Videos